

References

- Cascorbi I. (2012). Drug interactions--principles, examples and clinical consequences. *Deutsches Arzteblatt international*, 109(33-34), 546–556. <https://doi.org/10.3238/arztebl.2012.0546>
- Conroy, K. (2017). Reducing the burden of CVD in Indonesia. The George *Institute for Global Health*. 42.
- Coronary artery disease: Overview. (2017, July 27). Retrieved September 24, 2020, from <https://www.ncbi.nlm.nih.gov/books/NBK355313/>
- Dieks, J. K., Klehs, S., Müller, M. J., Paul, T., & Krause, U. (2016). Adjunctive ivabradine in combination with amiodarone: a novel therapy for pediatric congenital junctional ectopic tachycardia. *Heart Rhythm*, 13(6), 1297-1302.
- Doherty, P., Kirsas, S., Chao, S., Wiltshire, S., McKnight, D., Maxwell, D., ... & Graudins, L. (2004). SHPA standards of practice for drug use evaluation in Australian hospitals: SHPA Committee of Specialty Practice in Drug Use Evaluation. *Journal of Pharmacy Practice and Research*, 34(3), 220-223.
- Doligalski, C. T., Tong Logan, A., & Silverman, A. (2012). Drug interactions: a primer for the gastroenterologist. *Gastroenterology & hepatology*, 8(6), 376–383.
- Food and Drug Administration. (2019). Farxiga Full Prescribing Information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202293s018lbl.pdf
- Florek, J. (2020, May 08). Amiodarone. Retrieved September 24, 2020, from <https://www.ncbi.nlm.nih.gov/books/NBK482154/>
- Georgiopoulou, V. V., Kalogeropoulos, A. P., Raggi, P., & Butler, J. (2010). Prevention, diagnosis, and treatment of hypertensive heart disease. *Cardiology clinics*, 28(4), 675-691.
- Hsia, D. S., Grove, O., & Cefalu, W. T. (2017). An update on SGLT2 inhibitors for the treatment of diabetes mellitus. *Current opinion in endocrinology, diabetes, and obesity*, 24(1), 73.
- Kementerian Kesehatan RI. (2014). Situasi Kesehatan Jantung. Pusat Data dan Informasi Kementerian Kesehatan RI.
- Lam, C. S., Chandramouli, C., Ahooja, V., & Verma, S. (2019). SGLT-2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects. *Journal of the American Heart Association*, 8(20), e013389.
- Malik, A., Brito, D., & Chhabra, L. (2019). Congestive Heart Failure (CHF). NCBI Bookshelf Management Sciences for Health and World Health Organization. 2007. Drug and Therapeutics Committee Training Course.
- Morales-Ríos, O., Jasso-Gutiérrez, L., Reyes-López, A., Garduño-Espinosa, J., & Muñoz-Hernández, O. (2018). Potential drug-drug interactions and their risk factors in pediatric patients admitted to the emergency department of a tertiary care hospital in Mexico. *Plos One*, 13(1). doi:10.1371/journal.pone.0190882

- Pasina, L., Astuto, S., Cortesi, L., Tettamanti, M., Franchi, C., Marengoni, A., ... & REPOSI Investigators. (2016). Therapeutic duplicates in a cohort of hospitalized elderly patients: results from the REPOSI Study. *Drugs & aging, 33*(9), 647-654.
- Patiño-Rodríguez, O., Martínez-Medina, R. M., Torres-Roque, I., Martínez-Delgado, M., Mares-García, A. S., Escobedo-Moratilla, A., Covarrubias-Pinedo, A., Arzola-Paniagua, A., Herrera-Torres, J. L., & Pérez-Urizar, J. (2015). Absence of a significant pharmacokinetic interaction between atorvastatin and fenofibrate: a randomized, crossover, study of a fixed-dose formulation in healthy Mexican subjects. *Frontiers in pharmacology, 6*, 4. <https://doi.org/10.3389/fphar.2015.00004>
- Pittampalli, S., Upadyayula, S., Mekala, H. M., & Lippmann, S. (2018). Risks vs Benefits for SGLT2 Inhibitor Medications. *Federal Practitioner, 35*(7), 45.
- Regmi, M. (2020, August 10). Coronary Artery Disease Prevention. Retrieved September 24, 2020, from <https://www.ncbi.nlm.nih.gov/books/NBK547760/>
- Savarese, G., & Lund, L. H. (2017). Global public health burden of heart failure. *Cardiac failure review, 3*(1), 7.
- Scheen, A. J. (2014). Drug–drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus. *Clinical pharmacokinetics, 53*(4), 295-304.
- Scheen, A. J. (2015). Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease. *Clinical pharmacokinetics, 54*(7), 691-708.
- Shields, L., & Twycross, A. (2003). The difference between quantitative and qualitative research: this paper is one of a series of short papers on aspects of research by Linda Shields and Alison Twycross. *Paediatric nursing, 15*(9), 24-25.
- Siswanto, B. B., Radi, B., Kalim, H., Santoso, A., Suryawan, R., Antono, E., & Santoso, T. (2010). Heart Failure in NCVJ Jakarta and 5 hospitals in Indonesia. *CVD Prevention and Control, 5*(1), 35-38.
- Solimando, A. G., Argentiero, A., Ruckdeschel, A., Bittrich, M., & Schneider, A. (2017). Emerging Concepts in Acute Heart Failure: From the Pathophysiology to the Clinical Case Based Approach. *Int J Crit Care Emerg Med, 3*, 023.
- Tackling, G. (2020, June 28). Hypertensive Heart Disease. Retrieved September 24, 2020, from <https://www.ncbi.nlm.nih.gov/books/NBK539800/>
- Valderas, J. M., Starfield, B., Sibbald, B., Salisbury, C., & Roland, M. (2009). Defining comorbidity: implications for understanding health and health services. *The Annals of Family Medicine, 7*(4), 357-363.
- WHO Collaborating Centre for Drug Statistics Methodology. (2012). Guidelines for ATC classification and DDD assignment 2013. *Oslo*.
- Yayan, J. (2013). Emerging families of biomarkers for coronary artery disease: inflammatory mediators. *Vascular health and risk management, 9*, 435.